KRAS and ovarian carcinoma: One phase I study of the combination of trametinib and omipalisib in patients with advanced solid tumors revealed one partial response with a KRAS-mutant ovarian cancer patient who remained in the study for >400 days at the time of data analysis, one stable disease with an ovarian cancer patient, and one progressive disease in patients with uterine endometrial cancer [30].